Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

BM 13505

Known as: BM 13.505, BM-13505 
 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
1997
1997
The antithrombotic effect of desethyl KBT-3022, which is the main active metabolite of the new antiplatelet agent, KBT-3022… Expand
Is this relevant?
1995
1995
The effects of platelet-activating factor (PAF) on vascular resistance and capillary permeability were studied in the isolated… Expand
Is this relevant?
1994
1994
1. The objectives of the present experiments were to assess the role of ETA receptors in mediating endothelin-1 (ET-1)-induced… Expand
Is this relevant?
1993
1993
The antithrombotic effects of the thromboxane (TX) A2-receptor antagonist and aspirin were determined using a photochemically… Expand
Is this relevant?
1993
1993
The effects of KW-3635 (sodium (E)-11-[2-(5,6-dimethyl-1-benzimidazolyl) ethylidene]-6,11-dihydrodibenz-[b,e]oxepine-2… Expand
Is this relevant?
1992
1992
The purpose of the present experiments was to study the effects of endothelin-1 (ET-1) on vascular permeability and the… Expand
Is this relevant?
1992
1992
Thromboxane A2/prostaglandin H2 (TXA2/PGH2) receptors were characterized in rat vascular smooth muscle cells (VSMC). The specific… Expand
Is this relevant?
1989
1989
The ability of BM-13505, 4-[2-(4-chlorobenzenesulfonylamino) ethyl]-benzene acetic acid), a specific thromboxane/endoperoxide… Expand
Is this relevant?
1988
1988
Splanchnic artery occlusion (SAO) followed by release of the occlusive clamps produces circulatory shock characterized by an… Expand
Is this relevant?
1986
1986
The new specific thromboxane receptor antagonist, BM-13505, was infused intravenously (1 mg/kg bolus and 1 mg/kg hr continuous… Expand
Is this relevant?